Literature DB >> 28147352

Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Disease and Perspectives for Therapeutic Implication.

Dominik Bettenworth1, Florian Rieder.   

Abstract

BACKGROUND: Intestinal fibrosis with stricture formation is a common feature of inflammatory bowel disease (IBD) and leads to a significantly impaired quality of life in affected patients, intestinal obstruction as well as to the need for surgical intervention. This constitutes a major treatment challenge. Key Messages: Fibrosis results from the response of gut tissue to the insult inflicted by chronic inflammation. Similarly to what occurs in other organs, the underlying fibrogenic mechanisms are complex and dynamic, involving multiple cell types, interrelated cellular events, and a large number of soluble factors. Owing to a breakdown of the epithelial barrier in IBD, luminal bacterial products leak into the interstitium and induce an innate immune response mediated by the activation of both immune and non-immune cells. Other environmental factors as well as chronic inflammation will certainly impact the quality and quantity of intestinal fibrosis. Finally, the composition of the intestinal extracellular matrix is dramatically altered in chronic gut inflammation and actively promotes fibrosis through its mechanical properties. The conventional view that intestinal fibrosis is an inevitable and irreversible process is gradually changing in light of an improved understanding of the cellular and molecular mechanisms that underline its pathogenesis. In addition, clinical observations in patients who undergo strictureplasty have shown that stricture formation is reversible.
CONCLUSIONS: Identification of the unique mechanisms of intestinal fibrogenesis should create a practical framework to target and block specific fibrogenic pathways, estimate the risk of fibrotic complications, permit the detection of early fibrotic changes and, eventually, allow the development of treatment methods customized to each patient's type and degree of intestinal fibrosis.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2017        PMID: 28147352     DOI: 10.1159/000449079

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  16 in total

Review 1.  Interleukin-17: Friend or foe in organ fibrosis.

Authors:  Kritika Ramani; Partha S Biswas
Journal:  Cytokine       Date:  2019-02-14       Impact factor: 3.861

2.  Anti-Fibrotic Potential of All Trans Retinoic Acid in Inflammatory Bowel Disease.

Authors:  Dominick L Auci; Nejat K Egilmez; Gerald W Dryden
Journal:  J Gastroenterol Pancreatol Liver Disord       Date:  2018-05-28

3.  Tubercular Intestinal Strictures Show a Poor Response to Anti-Tuberculous Therapy.

Authors:  Piyush Aggarwal; Saurabh Kedia; Raju Sharma; Sawan Bopanna; Kumble Seetharama Madhusudhan; Dawesh P Yadav; Sandeep Goyal; Saransh Jain; Venigalla Pratap Mouli; Prasenjit Das; Siddhartha Dattagupta; Govind Makharia; Vineet Ahuja
Journal:  Dig Dis Sci       Date:  2017-08-30       Impact factor: 3.199

Review 4.  Epithelial-mesenchymal transition in Crohn's disease.

Authors:  H Jiang; J Shen; Z Ran
Journal:  Mucosal Immunol       Date:  2017-12-20       Impact factor: 7.313

Review 5.  Human Intestinal Mononuclear Phagocytes in Health and Inflammatory Bowel Disease.

Authors:  Charles Caër; Mary Jo Wick
Journal:  Front Immunol       Date:  2020-03-18       Impact factor: 7.561

6.  AXL Is a Potential Target for the Treatment of Intestinal Fibrosis.

Authors:  Calen A Steiner; Eva S Rodansky; Laura A Johnson; Jeffrey A Berinstein; Kelly C Cushing; Sha Huang; Jason R Spence; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2021-02-16       Impact factor: 7.290

7.  Diminished Vitamin D Receptor Protein Levels in Crohn's Disease Fibroblasts: Effects of Vitamin D.

Authors:  Laura Gisbert-Ferrándiz; Jesús Cosín-Roger; Carlos Hernández; Dulce C Macias-Ceja; Dolores Ortiz-Masiá; Pedro Salvador; Juan V Esplugues; Joaquín Hinojosa; Francisco Navarro; Sara Calatayud; María D Barrachina
Journal:  Nutrients       Date:  2020-04-01       Impact factor: 5.717

Review 8.  Potential Use of Human Stem Cell-Derived Intestinal Organoids to Study Inflammatory Bowel Diseases.

Authors:  Isabella Dotti; Azucena Salas
Journal:  Inflamm Bowel Dis       Date:  2018-11-29       Impact factor: 5.325

9.  Pirfenidone Inhibits Cell Proliferation and Collagen I Production of Primary Human Intestinal Fibroblasts.

Authors:  Yingying Cui; Mengfan Zhang; Changsen Leng; Tjasso Blokzijl; Bernadien H Jansen; Gerard Dijkstra; Klaas Nico Faber
Journal:  Cells       Date:  2020-03-22       Impact factor: 6.600

10.  Soluble Fraction from Lysate of a High Concentration Multi-Strain Probiotic Formulation Inhibits TGF-β1-Induced Intestinal Fibrosis on CCD-18Co Cells.

Authors:  Francesca Lombardi; Francesca Rosaria Augello; Paola Palumbo; Elona Mollsi; Maurizio Giuliani; Anna Maria Cimini; Maria Grazia Cifone; Benedetta Cinque
Journal:  Nutrients       Date:  2021-03-09       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.